ACADIA to Host Conference Call and Webcast on Thursday, November 5,2015, at 5:00 p.m. Eastern Time
SAN DIEGO—(BUSINESS WIRE)—Oct. 29, 2015—ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will report its unaudited financial results forthe third quarter ended September 30, 2015 on Thursday, November 5,2015, after the U.S. financial markets close. ACADIA's management willhost a conference call and webcast on Thursday, November 5, 2015, at5:00 p.m. Eastern Time to discuss ACADIA’s financial results andoperations.
The conference call may be accessed by dialing 844-821-1109 forparticipants in the United States or Canada and 830-865-2550 forinternational callers (reference passcode 69545890). A telephone replayof the conference call may be accessed through November 19, 2015 bydialing 855-859-2056 for callers in the United States or Canada and404-537-3406 for international callers (reference passcode 69545890).The conference call also will be webcast live on ACADIA’s website, www.acadia-pharm.comunder the investors section and will be archived there until November19, 2015.
About ACADIA Pharmaceuticals
ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has a pipeline of productcandidates led by NUPLAZID™ (pimavanserin), for which we have submitteda New Drug Application in Parkinson’s disease psychosis to the FDA andwhich has the potential to be the first drug approved in the UnitedStates for this condition. Pimavanserin is also in Phase II developmentfor Alzheimer’s disease psychosis and has successfully completed a PhaseII trial in schizophrenia. ACADIA also has clinical-stage programs forglaucoma and, in collaboration with Allergan, Inc., for chronic pain.ACADIA maintains a website at www.acadia-pharm.comto which we regularly post copies of our press releases as well asadditional information and through which interested parties cansubscribe to receive e-mail alerts.
Forward-Looking Statements
Statements in this press release that are not strictly historical innature are forward-looking statements. These statements include but arenot limited to statements related to the progress and timing of ACADIA’sdrug discovery and development programs, either alone or with a partner,including clinical trials, the benefits to be derived from ACADIA’sproduct candidates, in each case including NUPLAZID (pimavanserin), andthe potential for NUPLAZID to be the first drug approved in the UnitedStates for Parkinson’s disease psychosis. These statements are onlypredictions based on current information and expectations and involve anumber of risks and uncertainties. Actual events or results may differmaterially from those projected in any of such statements due to variousfactors, including the risks and uncertainties inherent in drugdiscovery, development, approval and commercialization, and incollaborations with others, and the fact that past results of clinicaltrials may not be indicative of future trial results. For a discussionof these and other factors, please refer to ACADIA’s annual report onForm 10-K for the year ended December 31, 2014 as well as ACADIA’ssubsequent filings with the Securities and Exchange Commission. You arecautioned not to place undue reliance on these forward-lookingstatements, which speak only as of the date hereof. This caution is madeunder the safe harbor provisions of the Private Securities LitigationReform Act of 1995. All forward-looking statements are qualified intheir entirety by this cautionary statement and ACADIA undertakes noobligation to revise or update this press release to reflect events orcircumstances after the date hereof, except as required by law.
Source: ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc.
Steve Davis, President andChief Executive Officer
Lisa Barthelemy, Director ofInvestor Relations
(858) 558-2871